PPT-TREATMENT OF MULTIDRUG-RESISTANT ACINETOBACTER BAUMANII OSTEOMYELITIS WITH ADJUNCTIVE

LT Christina Jamros DO Associate CDR Ryan Maves MD Fellow CAPT Mary Bavaro MD Fellow Department of Internal Medicine Naval Medical Center San Diego CA Disclosure I have no relevant financial relationships with any commercial supporters. The TB situation in 2013. :. Findings from the joint TB surveillance and monitoring report by . ECDC . and . the WHO Regional Office for Europe . ECDC TB Team. European Centre for Disease Prevention and Control. P. Stogsdill, MD, FIDSA. Sept 2013. Bad bugs, No drugs. NO ESKAPE. E. nterococcus . faecium. S. taphylococcus . aureus. K. lebsiella. . pneumoniae. . C. lostridium. . difficile. A. cinetobacter. ries 14 61 contributed data on 17690 isolates whichThese drugs are more costly toxic and less effective thanfirst-line drugs used for routine treatment of TB with other diseases resistance to TB drugs 31e Costly Burden of Drug-Resistant TB Disease in the USverage treatment costs per case 2018 dollarsMultidrug-resistant MDR tuberculosis disease is a major health threat globally Nearly half a million Septic Arthritis. Marwan . Shalabi. , MD, . FAAP, PIDS. Pediatric Infectious . Diseases. . Osteomyelitis. Classification. . Duration -------- . Acute or Chronic. Route of infection-. . Hematogenous. April 22,2014. Infection of the bone. Often confused with septic arthritis . Can occur in infants, children, and adults. Most commonly occurs:. Children. . ends of long bones in arms and legs. Adults. meningitis in the United States, 1993-2005. Presenter: . Christopher Vinnard. World Epidemiology Congress 2011. Edinburgh, Scotland. Disclosures. No authors have financial or non-financial conflicts of interests that may be relevant to this presentation. Dr Ali Abdulwahid . University of Mustanisiriya. College of Medicine. Department of Microbiology . Third stage . Yersinia . The genus Yersinia includes many species: . . Yersinia pestis . the (cause of plague). 1.BackgroundofresearchThereisanemergenceofmultidrugresistantbacteriawhichareunabletotreatwithmultipleantibacterialdrugs.Multidrugresistantbacterialinfectionsarebecominganimportantproblemfacinghealthca Last Updated: December 28, 2022. Prepared by:. David H. Spach, MD. Brian R. Wood, MD. Subcutaneous . Lenacapavir. Administer as Subcutaneous Injection. Take with or without food. Oral . Lenacapavir. Lenacapavir. CAPELLA. Lenacapavir. in Multidrug Resistant HIV. CAPELLA Study: Background. Source: Segal-Maurer S, et al. N . Engl. J Med. 2022;386:1793-1803. . Background. Phase 3, randomized, trial with oral and subcutaneous . John Stelling, MD, MPH, . jstelling@whonet.org. Brigham and Women’s Hospital, Harvard Medical School, Boston. WHO Collaborating Centre for Surveillance of Antimicrobial Resistance. Webinar agenda. Comments on the WHONET Webinar series. Kariuki S, Gilks C, Revathi G, Hart CA. Genotypic Analysis of Multidrug-Resistant Salmonella enterica Serovar Typhi, Kenya. Emerg Infect Dis. 2000;6(6):649-651. https://doi.org/10.3201/eid0606.000616. Identifying factors associated with adding adjunctive psychotherapy offers opportunities to identify individuals who may benefit from psychotherapy and potentially, from digital therapeutics and other alternative treatment approaches..